FY2023 EPS Estimates for Astria Therapeutics, Inc. (NASDAQ:ATXS) Cut by Analyst

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Analysts at HC Wainwright lowered their FY2023 EPS estimates for shares of Astria Therapeutics in a report released on Monday, November 13th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will earn ($1.93) per share for the year, down from their previous estimate of ($1.83). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($2.06) per share. HC Wainwright also issued estimates for Astria Therapeutics’ Q4 2023 earnings at ($0.54) EPS, FY2024 earnings at ($2.18) EPS, FY2025 earnings at ($2.70) EPS, FY2026 earnings at ($2.75) EPS and FY2027 earnings at ($2.86) EPS.

Several other brokerages also recently commented on ATXS. Oppenheimer cut their price target on shares of Astria Therapeutics from $30.00 to $25.00 and set an “outperform” rating on the stock in a report on Wednesday. Wedbush cut their price target on shares of Astria Therapeutics from $25.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, October 13th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $19.75.

Astria Therapeutics Trading Up 0.7 %

Shares of NASDAQ ATXS opened at $4.52 on Thursday. The stock has a market capitalization of $126.74 million, a price-to-earnings ratio of -2.05 and a beta of 0.90. Astria Therapeutics has a 12-month low of $4.27 and a 12-month high of $16.28. The firm’s 50-day moving average price is $6.25 and its 200-day moving average price is $8.70.

Insiders Place Their Bets

In related news, Director Perceptive Advisors Llc bought 1,074,608 shares of the company’s stock in a transaction on Monday, October 16th. The shares were acquired at an average cost of $6.51 per share, for a total transaction of $6,995,698.08. Following the purchase, the director now directly owns 1,652,371 shares of the company’s stock, valued at $10,756,935.21. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 3.40% of the company’s stock.

Institutional Investors Weigh In On Astria Therapeutics

Hedge funds have recently modified their holdings of the business. UBS Group AG lifted its position in shares of Astria Therapeutics by 66,700.0% in the 1st quarter. UBS Group AG now owns 2,672 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 2,668 shares during the period. Tower Research Capital LLC TRC lifted its position in Astria Therapeutics by 416.5% during the third quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 2,707 shares during the last quarter. California State Teachers Retirement System purchased a new stake in Astria Therapeutics during the second quarter valued at approximately $71,000. Citigroup Inc. purchased a new stake in Astria Therapeutics during the first quarter valued at approximately $117,000. Finally, Wells Fargo & Company MN lifted its position in Astria Therapeutics by 6,403.7% during the second quarter. Wells Fargo & Company MN now owns 10,536 shares of the biotechnology company’s stock valued at $88,000 after acquiring an additional 10,374 shares during the last quarter. Hedge funds and other institutional investors own 87.85% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema.